FOXD3 suppresses tumor growth and angiogenesis in non-small cell lung cancer

Biochemical and Biophysical Research Communications
Jun-Hai YanXi Zhou

Abstract

The transcription factor forkhead box D3 (FOXD3), widely studied as a transcriptional repressor in embryogenesis, participates in the carcinogenesis of many cancers. However, the expression pattern and role of FOXD3 in non-small cell lung cancer (NSCLC) have not been well characterized. We report that FOXD3 is significantly downregulated in NSCLC cell lines and clinical tissues. FOXD3 overexpression significantly inhibits cell growth and results in G1 cell cycle arrest in NSCLC A549 and H1299 cells. In a xenograft tumor model, FOXD3 overexpression inhibits tumor growth and angiogenesis. Remarkably, expression of vascular endothelial growth factor (VEGF) was reduced in FOXD3 overexpression models both in vitro and in vivo. These findings suggest that FOXD3 plays a potential tumor suppressor role in NSCLC progression and represents a promising clinical prognostic marker and therapeutic target for this disease.

References

Oct 17, 2002·Genes & Development·Lynn A HannaPatricia A Labosky
Jul 26, 2005·Developmental Biology·Dennie M TompersPatricia A Labosky
Jun 24, 2006·The Biochemical Journal·Patrick J E C WijchersMarten P Smidt
Oct 19, 2007·Nature Reviews. Cancer·Stephen S Myatt, Eric W-F Lam
Oct 25, 2008·Molecular Cancer·Paul P AnglimIte A Laird-Offringa
Dec 11, 2008·Pigment Cell & Melanoma Research·Aaron J Thomas, Carol A Erickson
Mar 9, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Xianhuo WangLijuan Chen
Apr 12, 2011·Molecular Cancer Research : MCR·Pragati Katiyar, Andrew E Aplin
Oct 2, 2012·Cancer Letters·Masuko KatohMasaru Katoh
Oct 13, 2012·Gastroenterology·Alfred S L ChengFrancis K L Chan
May 17, 2013·The Journal of Clinical Investigation·Ye ChenMichael Andreeff
Mar 19, 2014·Biochemical and Biophysical Research Communications·Tian-Li ChuJie Ge
Jul 26, 2014·Molecular Cancer Research : MCR·Michele B WeissAndrew E Aplin
Dec 3, 2014·Biochemical and Biophysical Research Communications·Zhan-Guo ZhangBi-Xiang Zhang
Jan 16, 2015·World Journal of Surgical Oncology·Ji-Chang HanYi-Jie Zhang

❮ Previous
Next ❯

Citations

Feb 6, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiao WangYandong Li
Mar 11, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zhai ErtaoWu Hui
Apr 22, 2017·Oncotarget·Huabin YinDianwen Song
Feb 13, 2018·Oncology Letters·Wenhua JiangXiaodong Li
Oct 27, 2018·International Journal of Molecular Sciences·Duc-Hiep BachSang Kook Lee
Apr 2, 2020·Frontiers in Cell and Developmental Biology·Xiao-Ling MaYi Lin
May 28, 2020·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Xiaoxing XieXiaoying Cui
Aug 31, 2017·Molecular Cancer Research : MCR·Shubhashish SarkarPomila Singh
Dec 22, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Roberto CostaLuigi Leanza
Feb 24, 2019·Trends in Molecular Medicine·Stephanie DoberschGuillermo Barreto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.